Yes, this 55-year-old postmenopausal woman should undergo a DEXA scan.
This patient meets multiple high-risk criteria that warrant osteoporosis screening despite being under age 65: postmenopausal status, chronic kidney disease, uncontrolled diabetes, and elevated alkaline phosphatase—all of which independently increase fracture risk and bone disease.
Rationale Based on Guidelines
The 2025 USPSTF guidelines explicitly recommend screening for postmenopausal women younger than 65 years who are at increased risk of osteoporosis, as determined by formal clinical risk assessment 1. While the guideline primarily focuses on age-based screening (≥65 years), it clearly states that this recommendation does not apply to individuals who have medical conditions associated with bone loss—which directly includes both CKD and diabetes 1.
Key Risk Factors Present
This patient has multiple compelling indications:
Chronic Kidney Disease: CKD is strongly associated with mineral and bone disorders (CKD-MBD). The 2025 KDIGO guidelines emphasize that DXA predicts fractures in CKD patients with comparable accuracy to the general population, and World Health Organization T-scores predict fracture risk similarly in patients with and without CKD 2. Bone quantity assessment via DXA is specifically recommended for CKD patients to guide treatment decisions.
Elevated Alkaline Phosphatase: This is a critical bone turnover marker. In CKD patients, elevated ALP correlates with increased mortality risk and suggests active bone disease 2. The elevation may indicate either increased osteoblastic activity or underlying bone pathology requiring assessment. High bone-specific alkaline phosphatase can help diagnose osteomalacia in the setting of vitamin D deficiency or mineral abnormalities 2.
Uncontrolled Diabetes: While the relationship between type 2 diabetes and bone density shows conflicting results in research, postmenopausal women with diabetes demonstrate significantly higher prevalence of osteoporosis despite sometimes paradoxically normal or higher BMD values 3, 4. The bone quality (not just quantity) is compromised in diabetes, making fracture risk assessment essential.
Postmenopausal Status: This alone increases fracture risk, and when combined with the above comorbidities, creates a multiplicative effect on bone health deterioration.
Screening Approach
Use a two-step approach as suggested by USPSTF 1:
- First: Apply a formal fracture risk assessment tool (such as FRAX) to quantify 10-year fracture probability
- Second: Proceed with DXA scanning given her multiple high-risk conditions
However, given this patient's constellation of risk factors (CKD + diabetes + elevated ALP + postmenopausal), you can reasonably proceed directly to DXA without formal risk calculation, as she clearly meets high-risk criteria.
What to Assess on DEXA
- Measure both hip and lumbar spine BMD 2
- Obtain T-scores for osteoporosis diagnosis
- Use results to guide bone-targeted therapy decisions
- In CKD patients specifically, DXA helps determine appropriate pharmacotherapy, as certain treatments (bisphosphonates) may be contraindicated in advanced CKD
Additional Workup Alongside DEXA
Given the elevated alkaline phosphatase and CKD, also measure:
- PTH levels (critical in CKD-MBD management) 2
- 25-OH vitamin D (commonly deficient in CKD)
- Serum calcium and phosphorus (part of integrative CKD-MBD strategy) 2
- Consider bone-specific alkaline phosphatase if available to differentiate bone vs. liver source
Common Pitfall to Avoid
Do not assume that diabetes provides "bone protection" because some studies show higher BMD in diabetic patients 3. The bone quality is compromised in diabetes, and fracture risk remains elevated despite normal or high BMD measurements. The DEXA is still essential for comprehensive assessment.
The combination of CKD, uncontrolled diabetes, and elevated alkaline phosphatase creates a high-risk scenario where early detection and intervention can significantly impact morbidity through fracture prevention 1, 2.